866-997-4948(US-Canada Toll Free)

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Apr 2014

Category :

Cancer

No. of Pages : 97 Pages

Bile Duct Cancer (Cholangiocarcinoma) Pipeline Review, H1 2014, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma)s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Bile Duct Cancer (Cholangiocarcinoma) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Bile Duct Cancer (Cholangiocarcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Bile Duct Cancer (Cholangiocarcinoma) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Bile Duct Cancer (Cholangiocarcinoma) Overview 8
Therapeutics Development 9
Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Overview 9
Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis 10
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies 11
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes 13
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies 16
Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes 17
Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development 18
AstraZeneca PLC 18
Eli Lilly and Company 19
Daiichi Sankyo Company, Limited 20
Panacea Pharmaceuticals, Inc. 21
Exelixis, Inc. 22
Access Pharmaceuticals, Inc. 23
OncoTherapy Science, Inc. 24
PCI Biotech AS 25
Provecs Medical GmbH 26
Agios Pharmaceuticals, Inc. 27
Cornerstone Pharmaceuticals, Inc. 28
NuCana BioMed Limited 29
Arrien Pharmaceuticals, LLC 30
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Target 33
Assessment by Mechanism of Action 36
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
vandetanib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
AP-5346 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
cabozantinib s-malate - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
elpamotide - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
exatecan mesylate - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
LY-2801653 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
CPI-613 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
(amphinex + gemcitabine) - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
WT-1 Peptide Vaccine + [gemcitabine] - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
NUC-1031 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
AG-120 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Im-01 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
PAN-622 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ARN-5032 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
JP-1584 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Bile Duct Cancer (Cholangiocarcinoma) - Recent Pipeline Updates 71
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects 90
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products 91
Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones 92
Featured News & Press Releases 92
Mar 12, 2014: Cornerstone Pharmaceuticals Lead Compound CPI-613 Demonstrates Ability to Disrupt Growth of Cancer Cells 92
Apr 10, 2013: Lilly Reveals Data Of LY2801653 At AACR Annual Meeting 93
Aug 14, 2012: Provecs Medical Receives US Patent Covering Technology Around Immunalon 93
Jan 10, 2012: Clinical Study Confirms Benitec\'s Gene-silencing Technology Is Safe And Effective In Fang Vaccine 94
Apr 07, 2009: Oncolytics Biotech Inc. Announces Positive Results of U.K. Phase II REOLYSIN and Radiation Combination Clinical Trial For The Trial REO 008 94

Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 97
Disclaimer 97

List of Table


Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2014 9
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by AstraZeneca PLC, H1 2014 18
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eli Lilly and Company, H1 2014 19
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 20
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Panacea Pharmaceuticals, Inc., H1 2014 21
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Exelixis, Inc., H1 2014 22
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Access Pharmaceuticals, Inc., H1 2014 23
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by OncoTherapy Science, Inc., H1 2014 24
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by PCI Biotech AS, H1 2014 25
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Provecs Medical GmbH, H1 2014 26
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals, Inc., H1 2014 27
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2014 28
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NuCana BioMed Limited, H1 2014 29
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Arrien Pharmaceuticals, LLC, H1 2014 30
Assessment by Monotherapy Products, H1 2014 31
Assessment by Combination Products, H1 2014 32
Number of Products by Stage and Target, H1 2014 35
Number of Products by Stage and Mechanism of Action, H1 2014 38
Number of Products by Stage and Route of Administration, H1 2014 40
Number of Products by Stage and Molecule Type, H1 2014 42
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics - Recent Pipeline Updates, H1 2014 71
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, H1 2014 90
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products, H1 2014 91

List of Chart


Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2014 9
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 31
Number of Products by Top 10 Target, H1 2014 33
Number of Products by Stage and Top 10 Target, H1 2014 34
Number of Products by Top 10 Mechanism of Action, H1 2014 36
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 37
Number of Products by Top 10 Route of Administration, H1 2014 39
Number of Products by Stage and Top 10 Route of Administration, H1 2014 40
Number of Products by Top 10 Molecule Type, H1 2014 41
Number of Products by Stage and Top 10 Molecule Type, H1 2014 42

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *